25/02/2026
به فضل خدا سه مقاله علمی مان در ژورنال های معتبر Lippincott و BMC Springer تحت عناوین ذیل قبول گردیده تا نشر شود که خلاصه آن قرار ذیل میباشد :
1️⃣ Neural Dust Technology: Toward Continuous Intracranial Monitoring
Neural dust is an emerging technology for continuous, minimally invasive intracranial monitoring. Using sub-millimeter ultrasonic-powered motes that wirelessly sense neural or pressure signals via backscattered ultrasound, it eliminates batteries and wired leads. Studies from the U.S., China, and Australia demonstrate feasibility for brain–computer interfaces and real-time mapping of neural activity and pressure, with potential applications in traumatic brain injury, stroke, and epilepsy. Challenges remain in biocompatibility, power delivery, and data security, but interdisciplinary collaboration could enable clinical translation and a new era of precision neurocritical care.
2️⃣ Trends and disparities in disseminated intravascular coagulation-related mortality among adults aged 25 and above in the U.S., 1999–2020: CDC WONDER insights
Disseminated intravascular coagulation (DIC) is a life-threatening coagulopathy often secondary to infection, malignancy, or obstetric complications. Using CDC WONDER data (1999–2020), 71,241 DIC-related deaths among U.S. adults ≥25 years were analyzed. Overall age-adjusted mortality declined from 2.1 to 1.6 per 100,000, but remained higher in men, non-Hispanic Black adults, those ≥85 years, rural residents, and people in the South and Northeast. Since 2017, mortality has increased, highlighting the need for targeted prevention and equitable critical care access.
3️⃣ The Role of Esketamine in Enhancing Postoperative Recovery and Pain Management
in Laparoscopic Surgery: A Meta-Analysis of Randomized Controlled Trials
Esketamine, an NMDA receptor antagonist, appears to improve early postoperative pain control and reduce rescue analgesia and postoperative nausea and vomiting (PONV) in laparoscopic surgery, without increasing adverse events. A meta-analysis of 11 RCTs (n = 1,036) showed significant reductions in pain scores at 0–6h and 12–24h, a 38% lower need for rescue analgesia, and a 26% reduction in PONV, though no differences were seen in emergence time, PACU stay, or 24-hour opioid use. Evidence certainty was moderate to low, with heterogeneity in dosing and analgesic regimens, highlighting the need for standardized, high-quality trials.
